Company Encyclopedia
View More
name
CanSinoBIO
688185.SH
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides.
1.601 T
688185.SHMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking24/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-2.84%D
    • Profit Margin-14.62%D
    • Gross Margin82.15%A
  • Growth ScoreB
    • Revenue YoY29.83%A
    • Net Profit YoY80.28%A
    • Total Assets YoY-8.62%E
    • Net Assets YoY-2.61%D
  • Cash ScoreC
    • Cash Flow Margin-684.22%E
    • OCF YoY29.83%A
  • Operating ScoreE
    • Turnover0.13E
  • Debt ScoreB
    • Gearing Ratio32.46%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    UBS: Slightly lowers the target price for CANSINOBIO to HKD 64, rating "Buy"

    UBS released a research report stating that it has raised the revenue forecasts for CanSinoBIO for 2026 and 2027 by 22% and lowered them by 9%, respectively. The earnings per share forecasts for 2025 to 2027 have been adjusted from 0.24, 1.16, and 2.55 yuan to 0.37, 1.41, and 2.34 yuan. The target price has been lowered from HKD 66 to HKD 64, with a rating of "Buy." CanSinoBIO's management indicated that the MCV4 vaccine contributed RMB 662 million in revenue in the first three quarters of this year, a year-on-year increase of approximately 28%, mainly due to the expansion of the applicable age group and continued channel penetration. MCV4 began exporting to Indonesia in the third quarter, and the bank estimates that it will record sales of several million this year. Additionally, since its launch in mid-year, PCV13i has entered about 12 provinces, with management aiming to cover half of the provinces by the end of the year and expand to other markets next year

    Zhitong·
    SH
    688185
    -0.26%
    HK
    06185
    -2.14%
    Zhitong·
    SH
    688185
    -0.26%
    HK
    06185
    -2.14%

    Understanding the Market | CanSinoBIO rises over 4% again, with third-quarter net profit increasing more than 8 times year-on-year, and core product ManHaiXin experiencing significant growth

    CANSINOBIO rose over 4% again, as of the time of writing, it increased by 3.84%, trading at HKD 45.98, with a transaction volume of HKD 25.5136 million. In terms of news, CANSINOBIO released its performance report, achieving an operating income of 310 million yuan in the third quarter, a year-on-year increase of 17.67%; the net profit attributable to shareholders of the listed company was 27.9256 million yuan, a year-on-year increase of 842.01%. In the first three quarters, it achieved an operating income of 693 million yuan, a year-on-year increase of 22.13%; the net profit attributable to shareholders of the listed company was 14.4401 million yuan, turning from loss to profit year-on-year. The announcement stated that the strong growth in CANSINOBIO's third-quarter performance was mainly due to the market performance of its core product, ManHaiXin. As one of the only four-valent meningococcal conjugate vaccine products in the field of meningococcal vaccines in China, ManHaiXin has demonstrated strong market performance due to its innovative advantages, continuously increasing its market share and driving the company's revenue growth of 22.13% year-on-year in the first three quarters

    Zhitong·
    SH
    688185
    -0.26%
    HK
    06185
    -2.14%
    Zhitong·
    SH
    688185
    -0.26%
    HK
    06185
    -2.14%

    Huachuang Securities: In the first three quarters, most vaccine varieties saw year-on-year growth in batch approvals, and pet vaccines continued to maintain a high growth rate

    Huachuang Securities released a research report stating that in the first three quarters of 2023, the batch issuance volume of most vaccine varieties increased year-on-year, especially with outstanding performance in pet vaccines and ruminant vaccines. Despite the pressure of internal competition in the animal husbandry industry, the prices of veterinary raw materials have stabilized and rebounded. Focus on undervalued and resilient targets. Specific data shows significant growth in pig vaccines, poultry vaccines, and pet vaccines, reflecting the positive impact of farming profitability and the launch of new products

    Zhitong·
    SH
    603392
    +0.13%
    SH
    600201
    +1.64%
    SH
    603566
    +0.35%
    Zhitong·
    SH
    603392
    +0.13%
    SH
    600201
    +1.64%
    SH
    603566
    +0.35%

    Understanding the Market | CanSinoBIO opened over 3% higher after earnings, with a net profit attributable to the parent company of 14.4401 million yuan in the first three quarters. The company will participate in the CPHI exhibition again

    CanSinoBIO opened over 3% higher after earnings, and as of the time of publication, it rose 3.36% to HKD 44.96, with a transaction volume of HKD 998,100. In terms of news, on October 27, CanSinoBIO released its performance for the first three quarters, achieving an operating income of 693 million yuan for the nine months ending September 30, 2025, a year-on-year increase of 22.13%; the net profit attributable to shareholders of the listed company was 14.4401 million yuan, compared to a net loss of 222 million yuan in the same period last year. The basic earnings per share were 0.06 yuan. It is worth mentioning that according to CanSinoBIO's official WeChat account, from October 28 to 30, the world's largest professional exhibition in the pharmaceutical industry—the CPHI Europe 2025—will be held in Frankfurt, Germany. CanSinoBIO will showcase its rich product line developed in-house, highlighting its outstanding advantages and deep accumulation in key areas such as innovative pneumonia vaccines, meningitis vaccines, and combined DTP vaccines, and will initiate innovative cooperation and business expansion in the global vaccine CRDMO field

    Zhitong·
    SH
    688185
    -0.26%
    HK
    06185
    -2.14%
    Zhitong·
    SH
    688185
    -0.26%
    HK
    06185
    -2.14%

    "Performance" CanSinoBIO earned 14.44 million RMB in the first three quarters, turning losses into profits

    CanSinoBIO announced its third-quarter report for the period ending in September, achieving operating revenue of 693 million RMB (the same below), an increase of 22.1% year-on-year. The net profit attributable to shareholders was 14.44 million RMB, compared to a loss of 222 million RMB in the same period last year, turning from loss to profit; earnings per share were 0.06 RMB

    AASTOCKS·
    SH
    688185
    -0.26%
    HK
    06185
    -2.14%
    AASTOCKS·
    SH
    688185
    -0.26%
    HK
    06185
    -2.14%